查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1982850

全球單株抗體市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Monoclonal Antibodies Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 175 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

單株抗體市場預計將從 2025 年的 3,065.3 億美元成長到 2034 年的 8,171.4 億美元，2026 年至 2034 年的複合年成長率為 11.51%。

隨著單株治療方法在現代醫學中日益重要，全球單株抗體市場正經歷快速成長。單株抗體是實驗室合成的分子，旨在靶向體內特定抗原。它們被廣泛用於治療多種疾病，包括癌症、自體免疫疾病和感染疾病，是先進生物療法的關鍵組成部分。

慢性病盛行率的上升和對標靶治療需求的日益成長推動了市場成長。單株抗體療法比傳統治療方法更精準，並改善了許多患者的治療效果。此外，生物技術和基因工程的不斷進步也推動了更有效的抗體藥物的研發。

隨著研發活動的不斷拓展，單株抗體市場前景十分光明。製藥公司正大力投資生物製藥的研發，從而不斷擴充抗體治療方法的產品線。隨著醫療體係日益重視個人化醫療和先進療法，單株抗體有望在未來的醫學創新中發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球單株抗體市場：依來源分類

  • 市場分析、洞察與預測
  • 小鼠來源
  • 嵌合體體
  • 人性化
  • 人類

第5章 全球單株抗體市場：依生產類型分類

  • 市場分析、洞察與預測
  • In Vivo
  • In Vitro

第6章 全球單株抗體市場：依應用分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 自體免疫疾病
  • 感染疾病
  • 神經系統疾病
  • 其他

第7章 全球單株抗體市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 專業醫療中心
  • 其他

第8章 全球單株抗體市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Merck & Co. Inc
    • Pfizer Inc
    • Novartis AG
    • AstraZeneca Plc
    • Roche Diagnostics（F. Hoffmann La Roche Ltd.）
    • Johnson & Johnson Services Inc
    • Eli Lilly And Company
    • Abbott Laboratories
    • Bayer AG
    • Amgen Inc
    • GlaxoSmithKline Plc
    • Merck KGaA
    • Sanofi SA
    • Daiichi Sankyo Company
    • Limited
    • Viatris Inc
簡介目錄
Product Code: VMR11212693

The Monoclonal Antibodies Market size is expected to reach USD 817.14 Billion in 2034 from USD 306.53 Billion (2025) growing at a CAGR of 11.51% during 2026-2034.

The global monoclonal antibodies market is experiencing rapid growth as these therapies become increasingly important in modern medicine. Monoclonal antibodies are laboratory-produced molecules designed to target specific antigens in the body. They are widely used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, making them a key component of advanced biological therapies.

The growth of this market is driven by the increasing prevalence of chronic diseases and the rising demand for targeted treatment options. Monoclonal antibody therapies offer higher precision compared to traditional treatments, improving treatment outcomes for many patients. Additionally, continuous advancements in biotechnology and genetic engineering are enabling the development of more effective antibody-based drugs.

The future outlook for the monoclonal antibodies market is highly promising as research and development activities continue to expand. Pharmaceutical companies are investing heavily in biologic drug development, leading to a growing pipeline of antibody-based therapies. As healthcare systems focus on personalized medicine and advanced treatments, monoclonal antibodies are expected to play a major role in future medical innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Source Type

  • Murine
  • Chimeric
  • Humanized
  • Human

By Production Type

  • In Vivo
  • In Vitro

By Application

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Others

By End Use

  • Hospitals
  • Specialty Centers
  • Others

COMPANIES PROFILED

  • Merck Co Inc, Pfizer Inc, Novartis AG, AstraZeneca plc, Roche Diagnostics F Hoffmann La Roche Ltd, Johnson Johnson Services Inc, Eli Lilly and Company, Abbott Laboratories, Bayer AG, Amgen Inc, GlaxoSmithKline plc, Merck KGaA, Sanofi SA, Daiichi Sankyo Company, Limited, Viatris Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY SOURCE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Source Type
  • 4.2. Murine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY PRODUCTION TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Production Type
  • 5.2. In Vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. In Vitro Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Neurological Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY END USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End Use
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Specialty Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MONOCLONAL ANTIBODIES MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Source Type
    • 8.2.2 By Production Type
    • 8.2.3 By Application
    • 8.2.4 By End Use
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Source Type
    • 8.3.2 By Production Type
    • 8.3.3 By Application
    • 8.3.4 By End Use
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Source Type
    • 8.4.2 By Production Type
    • 8.4.3 By Application
    • 8.4.4 By End Use
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Source Type
    • 8.5.2 By Production Type
    • 8.5.3 By Application
    • 8.5.4 By End Use
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Source Type
    • 8.6.2 By Production Type
    • 8.6.3 By Application
    • 8.6.4 By End Use
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MONOCLONAL ANTIBODIES INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Merck & Co. Inc
    • 10.2.2 Pfizer Inc
    • 10.2.3 Novartis AG
    • 10.2.4 AstraZeneca Plc
    • 10.2.5 Roche Diagnostics (F. Hoffmann La Roche Ltd.)
    • 10.2.6 Johnson & Johnson Services Inc
    • 10.2.7 Eli Lilly And Company
    • 10.2.8 Abbott Laboratories
    • 10.2.9 Bayer AG
    • 10.2.10 Amgen Inc
    • 10.2.11 GlaxoSmithKline Plc
    • 10.2.12 Merck KGaA
    • 10.2.13 Sanofi S.A
    • 10.2.14 Daiichi Sankyo Company
    • 10.2.15 Limited
    • 10.2.16 Viatris Inc